Business
Medpace provides outsourced clinical-development services to biotechnology and pharmaceutical companies.
Medpace converted biotechnology research demand into 20% growth, a 21% margin and nearly $700 million of free cash flow.
The read at a glance✓ Audited against SEC data
- Growth — Revenue grew 20.0%OK
- Profitability — Net income grew 11.6% to $451.123M from $404.386MOK
- Cash flow — Free cash flow grew 19.2% to $681.867M from $572.267MOK
- Margins — Operating margin contracted 5 bps to 21.14%Watch
- Accounting — Exceptional clinical-research executionNote
- Insiders — 0 purchases and 35 salesWatch
Where the revenue comes from
Fiscal 2025, as Medpace Holdings, Inc. reports it. History and quarterly detail are in the app.
- Oncology$747.6M
- Other$745.0M
- Metabolic$408.5M
- AVAI$254.8M
- Central Nervous System$239.4M
Leadership changes
From Medpace Holdings, Inc.'s own filings, the day they're filed.
- Brad W. Hansman · President · appointmenteff. 2026-06-01
- Ashley M. Keating · member · departureeff. 2024-06-30
- Pathology Chairs · president · appointment
Latest filings
- 10-Q · Quarterly report2026-07-23
- 8-K · Company announcement2026-07-22
- 8-K · Company announcement2026-06-04
- 8-K · Company announcement2026-05-19
- 10-Q · Quarterly report2026-04-23
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Medpace Holdings, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.